Dose- and schedule-dependent changes in vascular morphology after PI3K and PI3K/mTOR inhibition: in vitro vs. in vivo effects

Dose- and schedule-dependent changes in vascular morphology after PI3K and PI3K/mTOR inhibition: in vitro vs. in vivo effects

Bibliographic Details
Main Authors:	Fokas, E, Lechterier, T, Hackl, W, S-M, M, Mckenna, W, Hodivala-Dilke, K, Muschel, R
Format:	Conference item
Published:	2013

Similar Items

Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature.
by: Fokas, E, et al.
Published: (2012)

Regulation of O2 consumption by the PI3K and mTOR pathways contributes to tumor hypoxia
by: Kelly, C, et al.
Published: (2014)

Regulation of O2 consumption by the PI3K and mTOR pathways contributes to tumor hypoxia.
by: Kelly, C, et al.
Published: (2014)

Dual inhibition of PI3K and mTOR by VS-5584 suppresses thrombus formation
by: Thomas Später, et al.
Published: (2018-04-01)

PI3K/AKT/mTOR pathway in Angiogenesis
by: Jayashree eKarar, et al.
Published: (2011-12-01)

Targeting the PI3K/mTOR and ATR/Chk1 pathways to improve radiation efficacy for cancer therapy
by: Fokas, E
Published: (2012)

Targeting PI3K/Akt/mTOR Signaling In Cancer
by: Camillo ePorta, et al.
Published: (2014-04-01)

PI3K/Akt/mTOR inhibitors in breast cancer
by: Joycelyn JX Lee, et al.
Published: (2015-12-01)

SMER28 Attenuates PI3K/mTOR Signaling by Direct Inhibition of PI3K p110 Delta
by: Marco Kirchenwitz, et al.
Published: (2022-05-01)

Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma
by: Eun Jin Sun, et al.
Published: (2021-11-01)

Roles of PI3K/AKT/mTOR Axis in Arteriovenous Fistula
by: Stefano Ratti, et al.
Published: (2022-02-01)

PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer
by: Kunrui Zhu, et al.
Published: (2022-08-01)

Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies
by: Sarah K Tasian, et al.
Published: (2014-05-01)

In vitro effects of PI3K/mTOR inhibition in canine hemangiosarcoma.
by: Alex A Pyuen, et al.
Published: (2018-01-01)

AKTivation of the PI3K/AKT/mTOR signaling pathway by KSHV
by: Aadra P Bhatt, et al.
Published: (2013-01-01)

mTOR-Dependent and Independent Survival Signaling by PI3K in B Lymphocytes.
by: Mary Kaileh, et al.
Published: (2016-01-01)

Sequential dosing in chemosensitization: targeting the PI3K/Akt/mTOR pathway in neuroblastoma.
by: Mike-Andrew Westhoff, et al.
Published: (2013-01-01)

PI3K/AKT/mTOR Signaling Network in Human Health and Diseases
by: Tolulope O. Omolekan, et al.
Published: (2024-09-01)

A review of photobiomodulation on PI3K/AKT/mTOR in wound healing
by: Patricia Kasowanjete, et al.
Published: (2024-02-01)

Role of PTEN, PI3K, and mTOR in Triple-Negative Breast Cancer
by: Mirjana Prvanović, et al.
Published: (2021-11-01)

Targeting EGFR/PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma
by: Jieun Bang, et al.
Published: (2023-08-01)

Recent Advances in Dual PI3K/mTOR Inhibitors for Tumour Treatment
by: Xianbo Wu, et al.
Published: (2022-05-01)

Targeting the PI3K/Akt/mTOR signalling pathway in Cystic Fibrosis
by: R. Reilly, et al.
Published: (2017-08-01)

Combined PI3Kα-mTOR Targeting of Glioma Stem Cells
by: Frank D. Eckerdt, et al.
Published: (2020-12-01)

The PI3K/AKT/mTOR signaling pathway is overactivated in primary aldosteronism.
by: Hengchuan Su, et al.
Published: (2013-01-01)

Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer
by: Maira Michel, et al.
Published: (2011-08-01)

Assessments of prostate cancer cell functions highlight differences between a pan‐PI3K/mTOR inhibitor, gedatolisib, and single‐node inhibitors of the PI3K/AKT/mTOR pathway
by: Adrish Sen, et al.
Published: (2025-01-01)

Fibroblast-Induced Paradoxical PI3K Pathway Activation in PTEN-Competent Colorectal Cancer: Implications for Therapeutic PI3K/mTOR Inhibition
by: Fabiana Conciatori, et al.
Published: (2022-06-01)

PI3K/mTOR Dual Inhibitor PF-04691502 Is a Schedule-Dependent Radiosensitizer for Gastroenteropancreatic Neuroendocrine Tumors
by: Zeta Chow, et al.
Published: (2021-05-01)

Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML
by: Lindblad, O, et al.
Published: (2017)

Cyclophosphamide Inhibits PI3K/AKT/mTOR Signaling Pathway in Mice Kidneys
by: Gulsah Albayrak, et al.
Published: (2018-12-01)

Interaction of ncRNAs and the PI3K/AKT/mTOR pathway: Implications for osteosarcoma
by: Shao Weilin, et al.
Published: (2024-08-01)

Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia
by: Sophie Park, et al.
Published: (2010-05-01)

Inhibitors of the PI3K/Akt/mTOR Pathway in Prostate Cancer Chemoprevention and Intervention
by: Nazanin Momeni Roudsari, et al.
Published: (2021-08-01)

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
by: Antonino Glaviano, et al.
Published: (2023-08-01)

Downregulation of PI3K/AKT/mTOR Pathway in Juglone-Treated Bovine Oocytes
by: Marwa El-Sheikh, et al.
Published: (2023-01-01)

The Exosome-Mediated PI3K/Akt/mTOR Signaling Pathway in Neurological Diseases
by: Amin Iranpanah, et al.
Published: (2023-03-01)

Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours
by: Fei Xu, et al.
Published: (2020-04-01)

Research Progress on PI3K/AKT/mTOR Signaling Pathway in Burkitt Lymphoma
by: SUN Yuanyuan, et al.
Published: (2019-02-01)

Sinomenine inhibits the growth of melanoma by enhancement of autophagy via PI3K/AKT/mTOR inhibition
by: Sun Z, et al.
Published: (2018-08-01)